

GLOBAL MARKETS FOR DRUG REPURPOSING



PHM175A
January 2016

Shalini Shahani Dewan
Project Analyst

ISBN: 1-62296-202-8



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE REPORT	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
DEFINITIONS	10
DRUG	10
CHEMICAL DRUG	10
BIOLOGICAL DRUG	10
DRUG REPURPOSING	10
ACTIVE PHARMACEUTICAL INGREDIENT (API)	10
DRUG DEVELOPMENT	10
PHARMACEUTICAL DRUGS	10
CLASSIFICATION OF DRUGS	11
CHEMICAL OR SMALL MOLECULE DRUGS	11
BIOLOGIC DRUGS	11
<i>TABLE 1 COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC DRUGS</i>	12
HISTORY OF PHARMACEUTICAL DRUGS	13
<i>TABLE 2 EVOLUTION OF DRUG PRODUCTS</i>	13
DRUG DEVELOPMENT PROCESS	14
TARGET SELECTION/IDENTIFICATION	14
TECHNIQUES FOR TARGET IDENTIFICATION	15
TARGET VALIDATION	15
DRUG DISCOVERY/LEAD DISCOVERY	15
INITIAL SAFETY TESTS	16
LEAD OPTIMIZATION	16
PRECLINICAL TESTING	16
INVESTIGATIONAL NEW DRUG APPLICATION AND SAFETY	16
CLINICAL TRIALS	17
Phase I Clinical Trials	17
Phase II Clinical Trials	17

TOPIC	PAGE NO.
Phase III Clinical Trials	17
NEW DRUG APPLICATION AND APPROVAL	18
MANUFACTURING	18
PHASE IV TRIALS	18
DRUG REPURPOSING	19
LIPINSKI'S RULE OF 5 (RO5) AND EXTENSIONS	20
DEVELOPMENT OF REPURPOSED DRUGS	20
<i>TABLE 3 DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG REPURPOSING</i>	21
DRUG REPURPOSING METHODS	21
DRUG/TARGET-BASED	22
DISEASE-BASED	22
APPLICATION AREAS OF DRUG REPURPOSING	22
ADVANTAGES AND LIMITATIONS OF DRUG REPURPOSING	22
ADVANTAGES	23
Safety	23
Time and Cost-Effectiveness	23
High Market and Return Potential	23
Treatment of Rare Diseases	23
LIMITATIONS	24
Dependence on Public Data	24
Lack of Funding Opportunities	24
Lack of Familiarity with Regulatory Procedures	24
COMMON REPOSITIONED DRUGS	25
<i>TABLE 4 COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR UNDERGOING RESEARCH</i>	25
CHAPTER 4 REGULATORY ASPECTS	29
<i>TABLE 5 MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015</i>	29
RECALLS	30
<i>TABLE 6 RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015</i>	31
SAFETY ALERTS	32
<i>TABLE 7 SAFETY ALERTS FOR REPURPOSED DRUGS</i>	32
CHAPTER 5 TRENDS	35
DRUG REPOSITIONING IN PIPELINE	35
MERGERS AND ACQUISITIONS	36
<i>TABLE 8 MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES, 2010 TO APRIL 2015</i>	36
CURRENT SITUATION	39
FACTORS AFFECTING DRUG REPURPOSING	39
DRIVERS OF THE MARKET FOR DRUG REPURPOSING	39
Aging Population	39
Increased Prevalence of Chronic Diseases	40
Lifestyle Changes	40
Safety	40
Time and Economic Benefits	40
Advances in Drug Repurposing Methods	40
Treatment of Rare Diseases	41

TOPIC	PAGE NO.
RESTRAINTS AND CHALLENGES	41
Dependence on Public Data	41
Funding Opportunities	41
Lack of Understanding of Regulatory Issues	41
MARKET OPPORTUNITIES	41
CHAPTER 6 MARKET ANALYSIS	44
INTRODUCTION	44
MARKET BY REGION	45
MARKET REVENUE	45
TABLE 9 GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	46
FIGURE 1 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 (\$ MILLIONS)	46
MARKET SHARE	47
TABLE 10 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)	47
FIGURE 2 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)	47
MARKET BY APPLICATION	47
MARKET OVERVIEW	48
MARKET REVENUE	49
TABLE 11 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	50
FIGURE 3 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION, 2013-2020 (\$ MILLIONS)	50
MARKET SHARE	51
TABLE 12 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)	51
FIGURE 4 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)	51
CENTRAL NERVOUS SYSTEM DISORDERS	52
TABLE 13 TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS	52
Market Overview	53
Market Revenue	53
TABLE 14 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	53
FIGURE 5 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)	54
CARDIOVASCULAR DISORDERS	54
TABLE 15 TYPES OF CARDIOVASCULAR DISORDERS	55
Market Overview	55
Market Revenue	56
TABLE 16 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	56
FIGURE 6 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)	56
ONCOLOGY DISORDERS	57
TABLE 17 TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN	58
Market Overview	58
Market Revenue	59

TOPIC	PAGE NO.
<i>TABLE 18 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	60
<i>FIGURE 7 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION 2013-2020 (\$ MILLIONS)</i>	60
AUTOIMMUNE DISORDERS	60
<i>TABLE 19 TYPES OF AUTOIMMUNE DISEASES</i>	61
Market Overview	62
Market Revenue	63
<i>TABLE 20 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	63
<i>FIGURE 8 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)</i>	64
METABOLIC AND OTHER DISORDERS	64
Diabetes	64
Type 1 Diabetes	65
Type 2 Diabetes	65
Gestational Diabetes	65
Osteoporosis	65
Erectile Dysfunction	65
Benign Prostatic Hyperplasia (BPH)	65
Mediterranean Fever	65
Hemolytic Uremia Syndrome	66
Market Overview	66
Market Revenue	66
<i>TABLE 21 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	67
<i>FIGURE 9 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)</i>	67
MARKET ANALYSIS BY USAGE	68
MARKET OVERVIEW	68
MARKET REVENUE	69
<i>TABLE 22 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020 (\$ MILLIONS)</i>	69
<i>FIGURE 10 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 (\$ MILLIONS)</i>	69
MARKET ANALYSIS BY APPLICATION SITE	70
MARKET OVERVIEW	70
MARKET REVENUE	71
<i>TABLE 23 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE THROUGH 2020 (\$ MILLIONS)</i>	72
<i>FIGURE 11 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION SITE 2013-2020 (\$ MILLIONS)</i>	72
CHAPTER 7 INDUSTRY STRUCTURE	74
CENTRAL NERVOUS SYSTEM DISORDERS	74
MARKET LEADERS	74
<i>TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014</i>	74
MARKET SHARE	75

TOPIC	PAGE NO.
<i>TABLE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)</i>	75
<i>FIGURE 12 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)</i>	76
AUTOIMMUNE DISORDERS	76
MARKET LEADERS	76
<i>TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014</i>	77
MARKET SHARE	77
<i>TABLE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)</i>	77
<i>FIGURE 13 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)</i>	78
ONCOLOGY DISORDERS	78
MARKET LEADERS	78
<i>TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY DISORDERS, 2014</i>	78
MARKET SHARE	79
<i>TABLE 29 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014</i>	79
<i>FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014 (%)</i>	79
CARDIOVASCULAR DISORDERS	80
MARKET LEADERS	80
<i>TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014</i>	80
MARKET SHARE	80
<i>TABLE 31 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014</i>	81
<i>FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%)</i>	81
METABOLIC DISORDERS	82
MARKET LEADERS	82
<i>TABLE 32 LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014</i>	82
MARKET SHARE	82
<i>TABLE 33 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014</i>	82
<i>FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014 (%)</i>	82
OTHER DISORDERS	83
MARKET LEADERS	83
<i>TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014</i>	83
MARKET SHARE	84
<i>TABLE 35 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014</i>	84
<i>FIGURE 17 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014 (%)</i>	84
CHAPTER 8 PATENT ANALYSIS	87

TOPIC	PAGE NO.
PATENTS BY YEAR	87
<i>TABLE 36 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015</i>	88
<i>FIGURE 18 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015</i>	88
PATENTS BY COMPANY	88
<i>TABLE 37 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015</i>	88
<i>FIGURE 19 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015</i>	89
PATENTS BY COUNTRY	89
<i>TABLE 38 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015</i>	89
<i>FIGURE 20 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015</i>	89
<i>TABLE 39 PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%)</i>	90
<i>FIGURE 21 PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%)</i>	90
PATENTS BY ASSIGNEE	91
<i>TABLE 40 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015</i>	91
<i>FIGURE 22 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF PATENTS)</i>	91
CHAPTER 9 COMPANY PROFILES	94
ABBVIE INC.	94
ACTAVIS INC.	94
ALEXION PHARMACEUTICALS INC.	95
APOTEX INC.	95
AUROBINDO PHARMA LTD.	96
BIOGEN IDEC INC.	97
BIOVISTA INC.	97
CELGENE CORP.	98
DR. REDDY'S LABORATORIES LTD.	98
ELI LILLY & CO.	99
GLAXOSMITHKLINE	100
HOFFMANN-LA ROCHE AG	101
HOSPIRA INC.	101
JENKEN BIOSCIENCES INC.	102
JOHNSON & JOHNSON	102
MELIOR PHARMACEUTICALS INC	103
MERCK & CO. INC.	103
MYLAN PHARMACEUTICALS INC.	104
NOVARTIS AG	105
PAR PHARMACEUTICAL INC.	105
PFIZER INC.	106
SANDOZ	107
SANOFI	107
SOM BIOTECH SL	108
SOSEI GROUP LTD.	108
TAKEDA PHARMACEUTICALS U.S.A. INC.	109
TEVA PHARMACEUTICAL INDUSTRIES LTD.	109
UCB	110
ZYDUS CADILA GROUP	111
CHAPTER 10 APPENDIX I: ABBREVIATIONS	113

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC DRUGS	12
TABLE 2 EVOLUTION OF DRUG PRODUCTS	13
TABLE 3 DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG REPURPOSING	21
TABLE 4 COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR UNDERGOING RESEARCH	25
TABLE 5 MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015	29
TABLE 6 RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015	31
TABLE 7 SAFETY ALERTS FOR REPURPOSED DRUGS	32
TABLE 8 MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES, 2010 TO APRIL 2015	36
TABLE 9 GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	46
TABLE 10 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)	47
TABLE 11 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	50
TABLE 12 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)	51
TABLE 13 TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS	52
TABLE 14 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	53
TABLE 15 TYPES OF CARDIOVASCULAR DISORDERS	55
TABLE 16 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	56
TABLE 17 TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN	58
TABLE 18 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	60
TABLE 19 TYPES OF AUTOIMMUNE DISEASES	61
TABLE 20 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	63
TABLE 21 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, THROUGH 2020 (\$ MILLIONS)	67
TABLE 22 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020 (\$ MILLIONS)	69
TABLE 23 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE THROUGH 2020 (\$ MILLIONS)	72
TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014	74
TABLE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)	75
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014	77
TABLE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)	77
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY DISORDERS, 2014	78
TABLE 29 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014	79

TABLE HEADING	PAGE NO.
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014	80
TABLE 31 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014	81
TABLE 32 LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014	82
TABLE 33 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014	82
TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014	83
TABLE 35 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014	84
TABLE 36 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015	88
TABLE 37 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015	88
TABLE 38 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015	89
TABLE 39 PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%)	90
TABLE 40 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015	91

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 (\$ MILLIONS)	8
FIGURE 1 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION, 2013-2020 (\$ MILLIONS)	46
FIGURE 2 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%)	47
FIGURE 3 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION, 2013-2020 (\$ MILLIONS)	50
FIGURE 4 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014 (%)	51
FIGURE 5 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)	54
FIGURE 6 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)	56
FIGURE 7 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR ONCOLOGY DISORDERS BY REGION 2013-2020 (\$ MILLIONS)	60
FIGURE 8 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)	64
FIGURE 9 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND OTHER DISORDERS BY REGION, 2013-2020 (\$ MILLIONS)	67
FIGURE 10 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 (\$ MILLIONS)	69
FIGURE 11 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION SITE 2013-2020 (\$ MILLIONS)	72
FIGURE 12 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%)	76
FIGURE 13 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%)	78
FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR ONCOLOGY, 2014 (%)	79
FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%)	81
FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR METABOLIC DISORDERS, 2014 (%)	82
FIGURE 17 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR OTHER DISORDERS, 2014 (%)	84
FIGURE 18 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015	88
FIGURE 19 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015	89
FIGURE 20 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015	89
FIGURE 21 PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%)	90
FIGURE 22 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF PATENTS)	91